Background: Cystic fibrosis-related diabetes (CFRD) is associated with pulmonary decline, compromised nutritional status, and earlier mortality. Although diabetes technology is increasingly being used in individuals with CFRD, there is a paucity of data investigating the impact of hybrid closed loop (HCL) technology on glycemia in this patient population. Materials and Methods: In this multicenter retrospective study of 13 adults and adolescents with CFRD, 14 days of continuous glucose monitor data were analyzed at baseline, 1 and 3 months after transition to the Tandem t:slim X2 pump with Control IQ™ technology, a HCL system. Results: Control IQ initiation was associated with a significant increase in % time in target range (70-180 mg/dL), as well as decreases in average glucose, % time in hyperglycemic ranges (% time >180 mg/dL, % time >250 mg/dL), and glycemic variability (standard deviation, coefficient of variation). There was no significant change in % time in hypoglycemia ranges (% time <54 mg/dL, % time <70 mg/dL). Conclusions: To our knowledge, this is the first study to report a beneficial effect of Food and Drug Administration (FDA)-Approved HCL technology on glycemia in adults and adolescents with CFRD to date. Future studies are needed to understand the potential long-Term glycemic benefits of HCL devices and to explore the impact of this technology on heath-related quality of life, pulmonary function, nutritional status, and mortality.
|Original language||English (US)|
|Number of pages||7|
|Journal||Diabetes Technology and Therapeutics|
|State||Published - Jun 1 2022|
Bibliographical noteFunding Information:
M.S.P. received research funding from Vertex Pharmaceuticals in the form of an investigator initiated studies grant (unrelated to this study). The other authors have nothing to disclose.
© Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.
- Continuous glucose monitor
- Control IQ
- Cystic fibrosis-related diabetes
- Hybrid closed loop system
PubMed: MeSH publication types
- Journal Article
- Multicenter Study
- Research Support, N.I.H., Extramural